Ampreloxetine is being developed to address the root cause of blood pressure instability in multiple system atrophy, aiming ...

Strategic AI applications are helping life sciences teams overcome hidden bias, accelerate data discovery, and improve ...

The FDA will now publish adverse event data from FAERS on a daily basis, marking a major step toward greater transparency in drug development.

In this episode of the Applied Clinical Trials Brief, we recap our three most-viewed stories of the week—covering the Supreme Court’s decision to uphold NIH funding cuts tied to DEI, Phase II data ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient ...

This explainer unpacks how recent US policy shifts are reshaping diversity, equity, and inclusion in clinical research, ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing ...